Jun 18, 2019 13:11 JST

Source: Eisai

Eisai to Present Latest Data on Perampanel at 33rd International Epilepsy Congress

TOKYO, Jun 18, 2019 - (JCN Newswire) - Eisai Co., Ltd. announced today that the latest data on its antiepileptic drug (AED) perampanel (product name: Fycompa) will be presented at the 33rd International Epilepsy Congress (IEC) to be held from June 22 to 26, 2019 in Bangkok, Thailand.

As major presentations, 2 oral presentations will be given including on the final analysis of a Phase III clinical study (Study 311) on adjunctive perampanel in pediatric patients aged 4 to less than 12 years old with epilepsy. Also, a total of 12 poster presentations will be given, including on the primary analysis from a Phase III clinical study (FREEDOM / Study 342), which was conducted in Japan and South Korea, on the efficacy and safety of perampanel monotherapy in untreated epilepsy patients with partial-onset seizures (with or without secondary generalized seizures).

Perampanel is a first-in-class AED and a once-daily tablet discovered at Eisai's Tsukuba Research Laboratories. In the United States and Europe, an oral suspension formulation has been approved and is being marketed. The agent is a highly selective, noncompetitive AMPA receptor antagonist that reduces neuronal hyperexcitation by targeting glutamate activity at AMPA receptors on postsynaptic membranes. Perampanel is currently approved in countries around the world as an adjunctive therapy for the treatment of partial-onset seizures (with or without secondary generalized seizures) and primary generalized tonic-clonic seizures in patients with epilepsy 12 years of age and older. Furthermore, in the United States, Perampanel is approved for monotherapy and adjunctive use in the treatment of partial-onset seizures (with or without secondary generalized seizures) in patients with epilepsy 4 years of age and older.

Eisai considers neurology including epilepsy, a therapeutic area of focus, and strives to deliver perampanel throughout the world in pursuit of our mission to provide "seizure freedom" to a greater number of patients living with epilepsy. Eisai seeks to address the diverse needs of, as well as increasing the benefits provided to, patients with epilepsy and their families.

About perampanel (generic name, product name: Fycompa)

Perampanel is a first-in-class AED discovered and developed by Eisai. With epileptic seizures being mediated by the neurotransmitter glutamate, the agent is a highly selective, noncompetitive AMPA receptor antagonist that reduces neuronal hyperexcitation by targeting glutamate activity at AMPA receptors on postsynaptic membranes. Perampanel is available in tablet form to be taken once daily orally at bedtime. In addition, an oral suspension formulation has been approved and is being marketed in the United States and Europe.

Perampanel is currently approved in more than 55 countries, including the United States, Japan, in Europe and in Asia as adjunctive treatment for partial-onset seizures (with or without secondarily generalized seizures) in patients with epilepsy 12 years of age and older. An application seeking approval for use in the adjunctive treatment of partial-onset seizures is under review in China, which has been designated for Priority Review. In addition, perampanel has been approved in more than 50 countries, including the United States, Japan, in Europe and in Asia for treatment as an adjunctive therapy for tonic-clonic seizures in patients with generalized epilepsy 12 years of age and older. In the United States, perampanel is approved for monotherapy and adjunctive use in the treatment of partial-onset seizures (with or without secondarily generalized seizures) in patients with epilepsy 4 years of age and older. In Japan, a supplementary new drug application has been filed seeking approval of perampanel for use as monotherapy for partial-onset seizures, treatment for partial-onset seizures in pediatric patients aged 4 years and older, as well as a fine granule formulation. In Europe, an application has been submitted seeking the additional approval of perampanel for adjunctive use in the treatment of partial-onset seizures (with or without secondarily generalized seizures) or primarily generalized tonic-clonic seizures in pediatric patients with epilepsy.

Furthermore, Eisai is conducting a global Phase III clinical study (Study 338) for the agent in patients with epileptic seizures associated with Lennox-Gastaut syndrome.

Contact:
Public Relations Department,
Eisai Co., Ltd.
+81-(0)3-3817-5120
Source: Eisai
Sectors: BioTech

Copyright ©2024 JCN Newswire. All rights reserved. A division of Japan Corporate News Network.

Related Press Release


Lifenet and Eisai Co-Develop Dementia Insurance "be"
March 21 2024 16:36 JST
 
Eisai Selected as a Nadeshiko Brand 2024 as a Listed Company Excelling in Promotion of Women in the Workplace
March 21 2024 15:10 JST
 
Eisai Invests in C2N to Support Simplifying the Diagnosis of Early Alzheimer's Disease to Better Serve Patients
March 06 2024 16:47 JST
 
Eisai to Boost Initiatives on Greenhouse Gas Reduction, Aiming to Achieve Net Zero by 2050
February 21 2024 14:26 JST
 
Eisai Selected for 'Human Capital Leaders 2023' and 'Human Capital Management Gold Quality', Recognized as Company Committed to Excellent Management and Disclosure of Human Capital Initiatives
February 20 2024 08:35 JST
 
Eisai: Metoject Subcutaneous Injection Pen (Methotrexate) Pen-Type Autoinjector Approved in Japan
February 16 2024 08:31 JST
 
Eisai Commences Fully-Fledged Business Activities at Pharma Sales Subsidiary in South Africa
February 01 2024 17:04 JST
 
Eisai Submits New Drug Application for Mecobalamin Ultrahigh-Dose Formulation in Japan for the Indication of Amyotrophic Lateral Sclerosis
January 26 2024 15:26 JST
 
Eisai: Antiepileptic Drug Fycompa Injection Formulation Approved in Japan
January 18 2024 14:12 JST
 
Eisai Listed as a Global 100 Most Sustainable Corporation for the Eighth Time
January 17 2024 16:08 JST
 
More Press release >>

Latest Press Release


More Latest Release >>